Dewpoint launches with $60M series A to target biomolecular condensates

January 30th, 2019 | Biocentury

Dewpoint Therapeutics (Cambridge, Mass.) launched Wednesday with a $60 million series A round to fund development of its therapies targeting biomolecular condensates.

Full article